The downregulation of IGFBP3 has been shown in non-small cell lung cancer (NSCLC) cell lines resistant to cisplatin [23] and EGFR tyrosine kinase inhibitors (TKIs) [24], as well as in advanced colorectal patients non-responsive to chemotherapy [25]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.